Equity Research, Broker Reports, and media content on Novacyt SAS

  • Access the latest forecasts, broker valuations, multiples, and video content from the city about Novacyt SAS
  • See live updates from analysts, company announcements, and other news in a personalised/single dashboard
  • 02 Nov 21
Hybridan Small Cap Feast 02/11/2021

*A corporate client of Hybridan LLP Joiners Hostmore plc (MORE.L) has demerged from Electra Private Equity PLC, and the shares admitted to the Premium Segment of the Main Market.. Hostmore is a growing hospitality business with its current operations focused on the American-themed casual dining brand, Fridays, and the cocktail-led bar and restaurant brand, 63rd+1st. Leavers No leavers today. What’s cooking in the IPO kitchen? Ashtead Tech, subsea equipment rental and solutions provider for the g

Companies: VAL ALNOV GMR

  • 29 Jul 21
Small Cap Feast: 29/07/21

What’s cooking in the IPO kitchen? SpectrumX Holdings, a leader in proprietary formulations of HOCL (Hypochlorous Acid), is expected to list on the London Stock exchange. This Pre-IPO offering outlines opportunities for commercialisation of novel formulations of HOCL in the healthcare and pharmaceuticals markets. SpectrumX is focused on developing an inhaled respiratory treatment with blockbuster potential and has a sanitiser product that looks set to generate significant near-term revenues. T

Companies: ADME EDR EMR EMAN IOG MAB1 ALNOV ORPH SECN VTU

  • 12 Apr 21
SP Angel Healthcare Conditions- 12-04-2021


Companies: Novacyt SAS (ALNOV:PAR)C4X Discovery Holdings PLC (C4XD:LON)
  • 24 Mar 21
SP Angel Healthcare Conditions- 24-03-2021


Companies: Novacyt SAS (ALNOV:PAR)Feedback plc (FDBK:LON)
  • 24 Mar 21
Small Cap Feast

PensionBee, the online pensions provider, with a mission to make pensions simple, so that everyone can look forward to a happy retirement, considering an IPO on the High Growth Segment of the Main Market of the London Stock Exchange. PensionBee is a leading online pensions provider in the UK, with approximately 130,000 Active Customers and £1.5 billion of assets under administration , in each case as at 28 February 2020. Cornerstone FS to join AIM, an SME focused, cloud-based provider of inter

Companies: ADME AQX BLCC ANR HSP CEG TON FOX FDBK ALNOV

  • 17 Mar 21
SP Angel Healthcare Conditions- 17-03-2021


Companies: Novacyt SAS
  • 24 Feb 21
SP Angel Healthcare Conditions

Novacyt S.A. (NCYT.L*): R&D Update | N4 Pharma (N4P.L): Full year results

Companies: Novacyt SAS (ALNOV:PAR)N4 Pharma Plc (N4P:LON)
  • 04 Feb 21
FY20 trading update shows surge in sales

Novacyt recently announced a positive trading update for the year ended 31 December 2020 (FY20E). The update outlined the significant demand for the Group’s COVID-19 test offering over the period. Sales have resulted in a surge in revenues for FY20E which is 24- fold higher than FY19A revenues (€13.1m) and exceeded our estimates by €23.8m (SP Angel FY20E: €287.8m).

Companies: Novacyt SAS
  • 02 Feb 21
SP Angel Healthcare Conditions- 02-02-2021


Companies: Novacyt SAS
  • 29 Jan 21
SP Angel Healthcare Conditions- 29-01-2021

Novacyt S.A. (NCYT.L*): Trading update

Companies: Novacyt SAS
  • 05 Jan 21
SP Angel Healthcare Conditions- 05-01-2020


Companies: ALNOV HEMO MTFB

  • 21 Dec 20
Market Report: FTSE dives as Europe shut its doors to UK
market-report-ftse-dives-as-europe-shut-its-doors-to-uk
  • 21 Dec 20
Market Report: FTSE dives as Europe shuts its doors to UK
market-report-ftse-dives-as-europe-shuts-its-doors-to-uk
  • 21 Dec 20
SP Angel Healthcare Conditions- 21-12-2020

Novacyt (NCYT.L): COVID-19 tests can detect new COVID-19 strains

Companies: Novacyt SAS
  • 14 Dec 20
SP Angel Healthcare Conditions- 14-12-2020

Novacyt S.A.: Development of three new tests

Companies: Novacyt SAS

Novacyt SAS

Company Profile

  • Personnel
  • Anthony Dyer, CFO
  • Graham Mullis, CEO

Research, Charts & Company Announcements

Research Tree provides access to ongoing research coverage, media content and regulatory news on Novacyt SAS. We currently have 75 research reports from 4 professional analysts.

Latest News/RNS

(more news)
Date Source Announcement
13May22 07:00 RNS Novacyt S.A. - Notice of Annual General Meeting
03May22 12:21 RNS Novacyt S.A. - Liquidity Agreement Update and Total Voting Rights
28Apr22 07:00 RNS Novacyt S.A. - Full year results and update on growth strategy
26Apr22 07:00 RNS Novacyt S.A. - DHSC dispute update
20Apr22 07:00 RNS Novacyt S.A. - Notice of Results and Investor Presentation
12Apr22 07:00 RNS Novacyt S.A. - Approval of COVID-19 test under CTDA legislation
01Apr22 11:45 RNS Novacyt S.A. - Liquidity Agreement Update and Total Voting Rights
Get free RNS email alerts

  • Frequency of research reports

     

  • Research reports on

    Novacyt SAS

  • Providers covering

    Novacyt SAS

  • 17 May 22
Confidence in profitable expansion rebuilding

2021 was a tough year which saw the non-repeat of highly profitable hand sanitiser sales, almost no Chinese sales and the impact of input/cost inflation. However, it successfully integrated 2 acquisitions, which enhance the portfolio and earnings quality, and locked in the planned synergies. With new distribution agreements (inc to China), and mitigations in place to claw back lost margin, VLG looks set to return to profitable growth. The platform is highly scalable and trades on just 5x EV/EBIT

Companies: Venture Life Group Plc
  • 17 May 22
First clinical evidence for LBP in asthma

MRx-4DP0004 is 4D Pharma’s oral, immunomodulatory, single strain Live Biotherapeutic product (LBP). The safety portion of this Phase 1/2 (Part A) met the primary endpoint of safety and tolerability, with five secondary endpoints qualitatively improved over the placebo arm. The data is being presented in poster session at the ATS meeting May 15-18, 2022.

Companies: 4d Pharma PLC
  • 17 May 22
Bugs as drugs...and vaccines

4D Pharma is a pharmaceutical company developing Live Biotherapeutic Products (LBPs), a novel class of drug derived from the human gut microbiome. This differentiated approach focuses on leveraging the interactions of LBPs with host biology, underpinned by a proprietary MicroRx® platform. This has generated a strong clinical and preclinical pipeline of single strain LBPs targeting major diseases across multiple therapeutic area. A well flagged cash requirement overshadows the stock but the exper

Companies: 4d Pharma PLC
  • 06 May 22
Morning Note – 6 May 2022


Companies: SDI Group plc
  • 06 May 22
Cenkos: Healthcare Sector -- Ward Round

Weekly round-up of AIM-listed healthcare news. Intelligent Ultrasound, Inspiration Healthcare, Agronomics, CareTech Holdings, e-therapeutics, ABCAM, EKF Diagnostics, HUTCHMED (China), Benchmark Holdings, Totally, ImmuPharma, Open Orphan, Destiny Pharma, Polarean Imaging, Induction Healthcare.

Companies: ANIC RUA CREO GENI HEIQ IHC IXI IUG OPTI SBTX VAL VLG

  • 16 May 22
Morning Note – 16 May 2022


Companies: Kromek Group Plc (KMK:LON)Synairgen plc (SNG:LON)
  • 09 May 22
Morning Note – 9 May 2022


Companies: 4BB FOUR ARB IOF

  • 16 May 22
CMD demonstrated broader opportunity set

Yourgene’s Capital Markets Day on 26/4 provided a strong illustration of the significant strategic progress the group has made in recent years. The pandemic was both a blessing and a curse for YGEN, delaying some opportunities, but catalysing others and leaving the group in a stronger net position than where it started. The building blocks are now in place and, as healthcare markets normalise globally, we believe Yourgene is poised for a period of extended growth, with multiple opportunities to

Companies: Yourgene Health Plc
  • 13 May 22
Cenkos: Healthcare Sector -- Ward Round

Weekly round-up of AIM-listed healthcare news. Agronomics, Eden Research, IXICO, HeiQ, Trellus Health, NetScientific, Circassia, 4basebio, Fusion Antibodies, Surgical Innovations Group, Yourgene Health, Abingdon Health, Verici Dx, Poolbeg Pharma, Omega Diagnostics

Companies: ANIC RUA CREO GENI HEIQ IHC IXI IUG OPTI SBTX VAL VLG

  • 16 May 22
Hybridan Small Cap Feast 16/05/22

Dish of the day Joiners: No Joiners Today. Leavers: No Leavers Today. What’s cooking in the IPO kitchen? Lekoil, the oil and gas exploration and production Company with a focus on Nigeria and West Africa intends to join the AQSE Growth Market. The Company was previously listed on AIM (LEK.L), however, Ordinary Shares have been suspended from trading on AIM since October 2021. Due 18th May 2022. EnSilica, intends to join AIM. EnSilica is a designer and supplier of mixed signal Application Specifi

Companies: EEE FARN FCAP HZM JLP NSCI SRE

  • 12 May 22
Continued growth and margin improvement prompt further upgrades

A positive AGM update confirms strong revenue growth has continued YTD and further margin improvement means management again expect EBITDA to be materially ahead of expectations. The business model is now settled, with additional distributors appointed in the US which should help drive further penetration into the Primary Care market there. China revenues were strong and with no sign yet of any slowdown, despite being cognisant of renewed lockdowns there. Gross margins have remained robust on po

Companies: Circassia Group PLC
  • 17 May 22
Cenkos: Venture Life Group Plc -- FY21 results, positive outlook

Venture Life Group has reported its results for FY21A, with revenues and adjusted EBITDA coming in ahead of our forecasts. Revenues, supported by two acquisitions, grew 9% to £32.8m with the acquisitions more than offsetting lost FY20A COVID-related sales and significantly reduced shipments to China. The gross margin was also affected by these factors, though also supported by higher margin acquisitions. Adjusted EBITDA grew 8%. Management have provided a positive outlook for FY22E, based on tra

Companies: Venture Life Group Plc
  • 06 May 22
Omega Diagnostics - Placing raises £2.0m with Open Offer up to £2.0m

Omega Diagnostics has raised £2.0m, with up to £2.0m possible via an Open Offer to provide a bridge to the sale of the CD4 business and enable it to focus on the growth opportunities within its core business, Health & Nutrition. Having sold its Alva site in March for £1m, with a transitionary agreement put in place with Accubio until December 2022 to ensure the continued production of CD4 lateral flow tests, Omega has elected to sell the CD4 business, which would cost c.£1.5m to relocate to Ely

Companies: Omega Diagnostics Group PLC
  • 02 May 22
Farxiga + COVID-19 vaccine drives a strong Q1

Astra kicked-off 2022 on a good note, with solid growth in Farxiga and higher COVID-19 vaccine sales, off-setting weaknesses in lynchpin oncology and rare diseases. Although vaccine-driven top-line tailwinds are expected to dissipate soon, this is expected to be offset by a recovery in the core areas. In Q1, profitability again came under pressure but improved sequentially, and should improve further as the ‘young’ portfolio rolls over. Overall, decent results and our positive recommendation on

Companies: AstraZeneca PLC
  • 18 May 22
Hybridan Small Cap Feast 18/05/22

Dish of the day Joiners: Lekoil, the oil and gas exploration and production Company with a focus on Nigeria and West Africa has joined the Access Segment of the AQSE Growth Market. The Company was previously listed on AIM (LEK.L), however, Ordinary Shares have been suspended from trading on AIM since October 2021. Leavers: No Leavers Today. What’s cooking in the IPO kitchen? Psych Capital PLC, intends to list on the AQSE Growth Market. Psych operates the Psych Platform (a business-to-business ne

Companies: CZA AXL AEE CORA D4T4 EKF ORPH PWM PPH SYM

Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics. The company trades under the ticker Lon:NCYT